BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  McCarville, Justin L ^a   Nisemblat, Yotam ^b   Galipeau, Heather J ^a   Jury, Jennifer ^a   Tabakman, Rinat ^b   Cohen, Ad ^b   Naftali, Esmira ^b   Neiman, Bela ^b   Halbfinger, Efrat ^b   Murray, Joseph A ^c   Anbazhagan, Arivarasu N ^d   Dudeja, Pradeep K ^d   Varvak, Alexander ^e   Leroux, Jean Christophe ^f   Verdu, Elena F ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b BIOLINERX LTD   (Israel)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e BAR ILAN UNIVERSITY   (Israel)

^f ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; GASTROINTESTINAL AGENT; GLIADIN; GLUTEN; ORGANIC ANION TRANSPORTER 1; POLYHYDROXYETHYL METHACRYLATE POLYSTYRENESULFONIC ACID COPOLYMER; POLYMACON; POLYSTYRENESULFONIC ACID; UNCLASSIFIED DRUG; POLY(HYDROXYETHYL METHACRYLATE-CO-STYRENE SULFONATE); POLYSTYRENE DERIVATIVE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELIAC DISEASE; CELL MEMBRANE PERMEABILITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; LYMPHOCYTOSIS; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PERMEABILITY; RAT; SYNTHESIS; TOXICITY TESTING; TRANSGENIC MOUSE;

ANIMALIA; MUS; RATTUS;

ANIMALS; CELIAC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GLIADIN; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, TRANSGENIC; PERMEABILITY; POLYHYDROXYETHYL METHACRYLATE; POLYSTYRENES; PROTEIN BINDING; RATS; TOXICITY TESTS;

EID: 84909953992     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109972     Document Type: Article

References (36)

1. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647-655.
2. Abadie V, Sollid LM, Barreiro LB, Jabri B (2011) Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 29: 493-525.
3. Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ (2010) The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 7: 204-213.
4. Sollid LM, Jabri B (2013) Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol 13: 294-302.
5. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, et al. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297: 2275-2279.
6. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4: 713-717.
7. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, et al. (2003) Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Archives of internal medicine 163: 286.
8. Ludvigsson JF, Rubio-Tapia A, van Dyke CT, Melton LJ, 3rd, Zinsmeister AR, et al. (2013) Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 108: 818-824.
9. Green PH, Cellier C (2007) Celiac disease. N Engl J Med 357: 1731-1743.
10. Barker JM, Liu E (2008) Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv Pediatr 55: 349-365.
11. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA (2013) ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 108: 656-676; quiz 677.
12. Fasano A, Catassi C (2001) Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 120: 636-651.
13. Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, et al. (2007) A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 85: 160-166.
14. Fasano A, Catassi C (2012) Clinical practice. Celiac disease. N Engl J Med 367: 2419-2426.
15. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE (2012) The prevalence of celiac disease in the United States. The American journal of gastroenterology.
16. Lanzini A, Lanzarotto F, Villanacci V, Mora A, Bertolazzi S, et al. (2009) Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Alimentary pharmacology & therapeutics 29: 1299-1308.
17. Crespo Perez L, Castillejo de Villasante G, Cano Ruiz A, Leon F (2012) Nondietary therapeutic clinical trials in coeliac disease. Eur J Intern Med 23: 9-14.
18. Pinier M, Fuhrmann G, Verdu EF, Leroux JC (2010) Prevention measures and exploratory pharmacological treatments of celiac disease. Am J Gastroenterol 105: 2551-2561; quiz 2562.
19. Pinier M, Verdu EF, Nasser-Eddine M, David CS, Vézina A, et al. (2009) Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 136: 288-298.
20. Pinier M, Fuhrmann G, Galipeau HJ, Rivard N, Murray JA, et al. (2012) The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142: 316-325 e311-312.
21. Liang L, Pinier M, Leroux JC, Subirade M (2009) Interaction of a-gliadin with poly (HEMA-co-SS): Structural characterization and biological implication. Biopolymers 91: 169-178.
22. Galipeau HJ, Rulli NE, Jury J, Huang X, Araya R, et al. (2011) Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice. The Journal of Immunology 187: 4338-4346.
23. Correia JJ, Detrich HW (2008) Biophysical tools for biologists. London: Academic.
24. Thomas KE, Sapone A, Fasano A, Vogel SN (2006) Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 176: 2512-2521.
25. Verdu EF, Huang X, Natividad J, Lu J, Blennerhassett PA, et al. (2008) Gliadindependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 294: G217-225.
26. Tye-Din JA, Anderson RP, Ffrench RA, Brown GJ, Hodsman P, et al. (2010) The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clinical Immunology 134: 289-295.
27. Marsh MN (1992) Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 102: 330-354.
28. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN (2012) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24: 503-512.
29. Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Musu MP, et al. (2003) Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 52: 218-223.
30. Natividad JM, Huang X, Slack E, Jury J, Sanz Y, et al. (2009) Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS One 4: e6472.
31. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, et al. (2012) A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 107: 1554-1562.
32. Gopalakrishnan S, Tripathi A, Tamiz AP, Alkan SS, Pandey NB (2012) Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 35: 95-101.
33. Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, et al. (2012) Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 35: 86-94.
34. Simpson JE, Walker NM, Supuran CT, Soleimani M, Clarke LL (2010) Putative anion transporter-1 (Pat-1, Slc26a6) contributes to intracellular pH regulation during H+-dipeptide transport in duodenal villous epithelium. American Journal of Physiology-Gastrointestinal and Liver Physiology 298: G683-G691.
35. Simpson JE, Schweinfest CW, Shull GE, Gawenis LR, Walker NM, et al. (2007) PAT-1 (Slc26a6) is the predominant apical membrane Cl2/HCO32 exchanger in the upper villous epithelium of the murine duodenum. American Journal of Physiology-Gastrointestinal and Liver Physiology 292: G1079-G1088.
36. Walker NM, Simpson JE, Brazill JM, Gill RK, Dudeja PK, et al. (2009) Role of Down-Regulated in Adenoma Anion Exchanger in HCO3-Secretion Across Murine Duodenum. Gastroenterology 136: 893-901. e892.